Wan Tai Bio Rushes Into IPO Farmer Hill Spring Real Control Capital Territory A Shares

HUAWEI, Shun Feng, Lao Gan Ma and Wahaha have been dubbed "never listing four people". Among the famous but unlisted companies, the farmer's mountain spring, the first tier of bottled water in China, is also an important member.

Today, Shun Feng has been backdoor listing in 2017, and farmer Hill spring also has more links with the capital market.

In November 26th, it was reported that farmer Hill spring planned to raise funds in Hongkong IPO, or more than 1 billion US dollars. The news quickly aroused heated debate.

In December 23rd, for the IPO process, farmer Hill spring responsible person responded to the twenty-first Century economic report reporter, "no comment."

According to public reports, after several years of "listing" several times, farmer Hill spring has repeatedly clarified that there is no listing plan.

Close contact with the capital market is coming soon.

According to the official website of the SFC, Beijing Wan Tai bio pharmaceutical Limited by Share Ltd (hereinafter referred to as "Wan Tai bio") is scheduled to start in December 26th and will be examined by the 210th issuance examination committee in 2019.

This is Wan Tai bio two impact A shares. The chairman and real controller of Wan Tai bio Co., Ltd. are 83.56%. After this issue, the proportion of shares actually controlled will not be less than 75%, and still remain in the absolute controlling position.

Rushing IPO again

Wan Tai bio was founded in April 1991. It was first established as a Sino foreign joint venture and later acquired by Hongkong enterprise Hongkong Xinwei. In 2001, Hongkong Xinwei intended to transfer the biological stake of Wan Tai, and the 98.38% yuan's health hall cost 17 million 100 thousand yuan to buy 95% stake in Wan Tai bio.

The main business of Wan Tai bio is in vitro diagnostic reagents, in vitro diagnostic equipment and vaccine development, production and marketing. In the field of in vitro diagnostics, the company's products include HIV diagnostic reagents, hepatitis B diagnostic reagents and so on. In the field of vaccines, the company's products are mainly cervical cancer vaccines.

In June 2016, Wan Tai bio disclosed the prospectus for the first time, but the IPO process was terminated in December 29, 2017.

Since then, in November 2018, Wan Tai bio restarted IPO to raise 380 million yuan, which is mainly used for the automation transformation and internationalization certification of chemiluminescence reagents manufacturing system, the promotion and internationalization of the quality system of cervical cancer vaccine (HPV vaccine), and the expansion of marketing network center.

The hot cervical cancer vaccine has been "hard to find" in China.

Globally, only GlaxoSmithKline and Mercedes have the capacity to produce cervical cancer vaccines, and have the most advanced research and production technologies at the same time, leading the global cervical cancer vaccine update and iteration. Among them, GlaxoSmithKline's products are two valent cervical cancer vaccines, and the products of Mercedes are quadruvalent and nine valent cervical cancer vaccines.

A shares are listed on the list of cervical cancer vaccine related businesses. The agent is HPV and its nine valent vaccine.

According to the October Research Report of Minsheng securities, "according to the batch issued data in the first three quarters of 2019, the 4 price HPV vaccine batch issued 3 million 968 thousand (+4.2%), and the 9 price HPV vaccine batch issued 1 million 877 thousand (compared to +515%). At present, the number of HPV vaccines is still in short supply. In major cities, the current nine price HPV vaccine appointment time is more than 6 months, and the four price HPV appointment time is more than 3 months.

In twenty-first Century, the economic news reporter noted that Wan Tai bio worked for the two price cervical cancer vaccine and is currently in the stage of approval.

"Two valent, quadruvalent HPV vaccine can prevent about 70% of cervical cancer, and nine can prevent about 90% of cervical cancer. At present, the main demand is nine valent HPV vaccine, which is short of supply, and the demand for two price is relatively small. Two price HPV vaccine market space is too big to say. " Insiders told reporters 23 days ago.

Wan Tai bio pointed out in the prospectus, "at present, the company's two price cervical cancer vaccine has completed the three phase of clinical trials, declared in November 2017, and the State Food and drug administration is conducting a quick review. It is expected to be listed this year."

Zhong capital's Capital Territory

The disclosure of the Wan Tai bio Prospectus has also revealed the corner of the capital territory of Chung Hsin hall behind Zhong Wei.

Yang Sheng Tang is an investment company specializing in the field of health. Its main investment is drinking water, health care and health food, biomedicine, planting, etc. its holding businesses and products are related to drinking water and beverages, diagnostic reagents and vaccines, health products and health food products, cosmetics, planting and real estate. Zhong Yang holds 98.38% of the health hall.

Zhong Shanshan may be low-key, but from his hand, "farmer's mountain spring is a little sweet", "we do not produce water, we are only nature's porters" and other advertising slogans are popular.

The farmer's spring was founded in 1996 by Chung Chung. The health hall holds 65.52% of farmer's spring. Zheshang magazine published the list of the top 500 top 2018 businessmen in Zhejiang Province, showing that from 2013 to 2017, the revenue of farmer's spring rose from 9 billion yuan to 16 billion 250 million yuan, and was hit by new highs.

By the end of 2018, the unaudited total assets of farmer's spring were 20 billion 75 million yuan, net assets of 14 billion 411 million yuan, and net profit of 3 billion 616 million yuan. In the same period, the net profit of Kang master was 2 billion 463 million yuan.

Previously, farmer Hill spring had tried to sprint A shares IPO, the listing guidance period lasted for ten years. As early as 2008, farmer Hill spring signed a listing guidance agreement with CITIC Securities. The contents include listing relevant legal compilation materials, learning specific development goals and ways to achieve, adjusting the declaration plan, etc.

In October 2018, CITIC Securities submitted to the Zhejiang Securities Regulatory Commission a report on the twenty-eighth phase of counselling work of farmer Hill spring, indicating that the counselling work is progressing smoothly.

However, in December 2018, after the friendly consultation between the two sides, the farmer's spring and CITIC Securities signed the termination agreement of the counselling agreement. At that time, farmer Hill spring responsible person said that the company did not plan for listing, and did not need the strength of the capital market, so the termination of listing guidance.

However, in November 26th of this year, it was reported that farmer Hill spring planned to raise funds in Hongkong IPO, or more than 1 billion US dollars, as early as the first half of next year. The news quickly aroused heated debate.

For the IPO process, farmer Hill spring responsible person in December 23rd responded to the twenty-first Century economic report reporter, said, "no comment."